Hestia Insight (HSTA) 10-Q 14 Jul 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	May 31, 2023	Jul. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	May 31, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--11-30
Entity File Number	024-11289
Entity Registrant Name	HESTIA INSIGHT INC.
Entity Central Index Key	0001813603
Entity Tax Identification Number	85-0994055
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	400 S. 4th Street
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89101
City Area Code	(702)
Local Phone Number	793-4028
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,939,260

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	May 31, 2023	Nov. 30, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 151,278	$ 252,956
Investments in equities	153,092	268,898
Note receivable; net of allowance for doubtful accounts of $5,185 and $0 as of May 31, 2023, and November 30. 2022, respectively.		5,185
Lease contract receivable – short term		30,000
Total current assets	304,370	557,039
FIXED ASSETS:
Vending machines; net of accumulated depreciation of $14,426 and $0 as of May 31, 2023, and November 30. 2022, respectively.	98,522	106,196
Right-of-Use auto lease	3,136	6,900
Total fixed assets	101,658	113,096
OTHER ASSETS:
Lease contract receivable – long term		42,500
TOTAL ASSETS	406,028	712,635
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	11,479	9,689
Right-of-Use current liability	3,136	6,900
Unearned income on lease contract receivable		17,517
Total current liabilities	14,615	34,106
LONG TERM LIABILITIES:
TOTAL LIABILITIES	14,615	34,106
STOCKHOLDERS’ EQUITY:
Common stock, par value $0.001 per share; 285,000,000 shares authorized; 27,939,260 and 27,939,260 shares issued and outstanding as of May 31, 2023, and November 30, 2022, respectively.	27,939	27,939
Treasury Stock, 5,100,000 and 5,100,000 shares as of May 31, 2023, and November 30. 2022, respectively.	5,100	5,100
Additional paid in capital	901,613	901,613
Accumulated earnings/(deficits)	(543,239)	(256,123)
Total stockholders’ equity	391,413	678,529
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 406,028	$ 712,635

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	May 31, 2023	Nov. 30, 2022
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 5,185	$ 0
Accumulated depreciation	$ 14,426	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	285,000,000	285,000,000
Common stock, shares issued	27,939,260	27,939,260
Common stock, shares outstanding	27,939,260	27,939,260
Treasury stock, shares shares	5,100,000	5,100,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2023	May 31, 2022	May 31, 2023	May 31, 2022
REVENUE:
Total revenue	$ 30,000		$ 30,500
OPERATING EXPENSE:
Selling, general and administrative expense	86,212	56,753	226,935	192,611
Total operating expense	86,212	56,753	226,935	192,611
OPERATING INCOME/(LOSS)	(56,212)	(56,753)	(196,435)	(192,611)
OTHER INCOME/(EXPENSE):
Interest income		73		148
Interest income on lease receivable		604		3,020
Dividend income	750		1,650
Gain/(loss) on sale of capital assets	(25,233)		(25,233)
Realized gain/(loss) on equity investments	4,997	74,042	32,607	133,834
Unrealized gain/(loss) on equity investments	(44,113)	(99,787)	(94,520)	(1,623,482)
Interest expense
Bad debt expense			(5,185)
Total other income/(expense)	(63,599)	(25,068)	(90,681)	(1,486,480)
INCOME/(LOSS) BEFORE TAXES	(119,811)	(81,821)	(287,116)	(1,679,091)
Tax expense	0	0	0	0
NET INCOME/(LOSS)	$ (119,811)	$ (81,821)	$ (287,116)	$ (1,679,091)
Basic net income/(loss) per common share	$ 0	$ 0	$ (0.01)	$ (0.06)
Diluted net income/(loss) per common share	$ 0	$ 0	$ (0.01)	$ (0.06)
Ave. common shares outstanding – Basic & Diluted	27,939,260	27,939,200	27,939,260	27,939,260
Consulting Revenue [Member]
REVENUE:
Total revenue	$ 30,000		$ 30,500

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Series B Common Stock [Member]	Preferred Stock [Member]	Treasury Stocks [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Nov. 30, 2020	$ 27,910	$ 500		$ 4,600	$ 814,337	$ 11,224,215	$ 12,071,562
Beginning balance, shares at Nov. 30, 2020	27,910,200	500,000
Issuance of Hestia Insight Inc. common stock for services valued at $48,750	$ 6				12,354		12,360
Issuance of Hestia Insight Inc. common stock for services valued, shares	6,000
Cancellation of Hestia Insight Inc. Series B common stock.		$ (500)		500
Cancellation of Hestia Insight Inc. Series B common stock, shares		(500,000)
Net Loss for 6-month period						(9,766,417)	(9,766,417)
Ending balance, value at Nov. 30, 2021	$ 27,916			5,100	826,691	1,457,798	2,317,505
Ending balance, shares at Nov. 30, 2021	27,916,200
Issuance of Hestia Insight Inc. common stock for services valued at $48,750	$ 15				48,735		48,750
Issuance of Hestia Insight Inc. common stock for services valued, shares	15,000
Issuance of Hestia Insight Inc. common stock for cash	$ 8				26,187		26,195
Issuance of Hestia Insight Inc. common stock for cash, shares	8,060
Net Loss for 6-month period						(1,713,912)	(1,713,921)
Ending balance, value at Nov. 30, 2022	$ 27,939			5,100	901,613	(256,123)	678,529
Ending balance, shares at Nov. 30, 2022	27,939,260
Net Loss for 6-month period						(287,116)	(287,116)
Ending balance, value at May. 31, 2023	$ 27,939			$ 5,100	$ 901,613	$ (543,239)	$ 391,413
Ending balance, shares at May. 31, 2023	27,939,260

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	May 31, 2023	May 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income/(Loss)	$ (287,116)	$ (1,679,091)
Adjustments to reconcile net income/(loss) to operating cash flows:
Issuance of common stock for services		48,750
Realized loss on sale of capital assets	25,233
Realized loss (gain) on investment equities	(32,607)	(133,834)
Unrealized loss (gain) on investment equities	94,520	1,598,895
Depreciation expense	10,809
Bad Debt Expense	5,185
Changes in operating asset and liability account balances:
Accounts receivable and lease interest receivable		12,362
Accounts payable and accrued interest payable	1,790	(14,988)
NET ADJUSTMENTS	104,930	1,511,185
NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES	(182,186)	(167,906)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds used in purchase of equipment leased to others		(68,255)
Proceeds used in purchase of vending machines	(385)
Proceeds from sale of capital assets	27,000
Proceeds used in purchase of investment equities	(22,140)
Proceeds provided by investment equities	76,033	133,834
NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES	80,508	65,579
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds provided by issuance of common stock		26,195
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES		26,195
NET INCREASE (DECREASE) IN CASH	(101,678)	(76,132)
CASH – BEGINNING OF PERIOD	252,956	524,741
CASH – END OF PERIOD	$ 151,278	$ 448,609

Organization and basis of accou

Organization and basis of accounting	6 Months Ended
	May 31, 2023
Accounting Policies [Abstract]
Organization and basis of accounting	Note 1 – Organization and basis of accounting Nature of Organization Hestia Insight Inc., (“Hestia” or the “Company”) was incorporated in the State of Nevada on November 19, 2003, and was formerly known as Luxshmi Investments, Inc. until it changed its name on March 27, 2019. The Company is focused primarily on the healthcare and biotech sectors through the Company’s two wholly owned operating subsidiaries, Hestia Investments Inc. (“Hestia Investments”), and HSTA HEALTH INC., d/b/a Hestia Vending (“Hestia Vending”). Hestia Investments provides strategic consulting, medical supply sales and marketing support, management, and capital markets advisory services for select micro, small and medium sized companies within the healthcare and biotech sectors. Hestia Vending operates within the healthy food, beverage and wellness products industry and the smart vending machine industry. The Company is positioned to make strategic acquisitions of emerging growth companies with unique sciences and technologies. The Company intends to pursue the acquisition and development of healthcare related technologies in the healthcare and biotech sectors through acquisition, licensing, or joint ventures. The Company will also consider a third avenue of investing in certain technologies. The Company entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies. Basis of Presentation The accompanying consolidated financial statements include the accounts of Hestia Insight Inc. (“Hestia” or the “Company”) consolidated with the accounts of its wholly owned subsidiaries Hestia Investments, Inc., a Wyoming corporation and HSTA Health, Inc., d/b/a Hestia Vending, a Nevada corporation. In these notes, the terms “us,” “we” or “our” refer to Hestia Insight Inc. and its consolidated subsidiary. The accompanying financial statements are prepared on the basis of accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company is a development stage enterprise devoting substantial efforts to establishing its new business, financial planning, raising capital, and research into investments and services which may become part of the Company’s investment and services portfolios. The Company has not realized significant revenues from inception through the date of these financial statements. A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and, even if planned principal operations have commenced, revenues are insignificant. Presented as a Going Concern The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect. While management of the Company believes that it will be successful in its capital formation and planned operating activities, there can be no assurance that we will be able to raise additional equity capital or be successful in the development and commercialization of the investments and services it develops or enters into collaboration agreements thereon. Ultimately, the Company will need to achieve profitable operations in order to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the reclassification or the amounts that can be recovered from receivables or other assets, or the reclassification or the amounts of liabilities that may result from the possible inability of the Company to continue as a going concern.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	May 31, 2023
Accounting Policies [Abstract]
Summary of significant accounting policies	Note 2 – Summary of significant accounting policies Cash and Cash Equivalents For purposes of reporting within the balance sheets and the statements of cash flows, the Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, cash on deposit in attorney trust accounts, and all highly liquid debt instruments purchased with a maturity of six months or less to be cash and cash equivalents. Prepaid Expenses The Company records amounts which have been paid in advance of receiving future economic benefits anticipated by the payment as prepaid expenses. Prepaid expenses are recorded as assets and expensed over the period that the benefits are received from the payment. The Company recorded as prepaid expenses of $ 0 0 Right-of-Use Assets The Company recognizes operating lease assets and lease liabilities in accordance with ASU 2016-02, “Leases (Topic 842).” ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases and makes certain changes to the accounting for lease expenses. The Company has adopted this standard starting for the year ending November 30, 2020, the first year the Company had any leased assets. This standard requires us to increase our assets and liabilities by equal amounts through the recognition of right-of-use assets and lease liabilities for our operating leases and to recognize the initial and the monthly payments as operating expenses when paid or accrued on our Consolidated Statements of Operations and Consolidated Statements of Cash Flows. On November 2, 2020, the Company entered into an operating lease to lease an automobile for a net initial payment of $ 4,029 627 3,763 3,763 3,136 3,136 Lease Contracts Receivable The Company recognizes its participation as a lessor in direct financing leases in accordance with ASU 2016-02, “Leases (Topic 842).” Topic 842 is now recognized as ASC 842 and the Company has adopted this new standard effective for all fiscal years starting on and after December 1, 2021. In accordance with ASC 842 the Company does not recognize the ownership of assets as a lessor in direct financing lease arrangements. Instead, when the Company originates the lease, it records a net investment in the lease on the balance sheet. The asset amount is a lease contract receivable equal to the present value of all the lease payments to be received and listed as both short term and long-term receivables on the balance sheet. The liability amount is equal to the difference between the present value of the lease contract receivable and the cost of leased equipment. The liability amount represents the unearned interest income that will be earned by the lessor over the term of the lease, and it is listed as u On December 2, 2021, the Company entered into a direct financing lease as a lessor of $ 68,255 2,500 90,000 68,255 21,745 0 3,020 Termination of Lease Contracts Receivable In accordance with ASC 842 and ASC 842-30-40 if a direct financing lease is terminated before the end of the lease term the Company will reclassify the net investment in the lease as a fixed asset. The value of the fixed asset is equal to the net lease asset amount (the lease asset amount less the lease liability amount) at the time of termination reduced by any impairment in the value in the fixed asset. On December 1, 2022, the Company terminated the above-described direct financing lease due to lack of payment from the lessee and repossessed the computer equipment. At the time of the termination, the net investment in the lease was recorded as a $54,983 fixed asset of computer equipment calculated as the net of a $72,500 asset as a lease contract receivable less a $17,517 liability as unearned income on the lease receivable. On April 4, 2023, the Company sold the equipment for $ 27,000 25,233 Investments in Equities ASC Topic 820, Fair Value Measurements and Disclosures ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows: ● Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. For those investments in equities, including equity securities and partnership interests, that have a “readily determinable fair value,” as defined in ASC Topic 321 and discussed below, or are traded in a verifiable public market and are not restricted for sale in the public market by a restricted stock legend, or can otherwise be reasonably valued using the three levels of the fair value hierarchy under ASC Topic 820 discussed above, we present and carry our investments at their estimate of fair value at net asset value (NAV) as of the balance sheet date. For these equity securities and partnership interests we include the realized and unrealized gains and losses arising from the changes in the fair values during the period as a component of investment gains in the consolidated statements of operations. For those investments in equities, including equity securities and partnership interests, that do not have a “readily determinable fair value,” or are not traded in a verifiable public market or are restricted for sale in the public market by a restricted stock legend or otherwise, we present and carry our investments using the measurement alternative which is cost minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined in ASC 321, for the identical or a similar investment of the same issuer. Income Taxes The Company accounts for income taxes pursuant to FASB ASC Topic 740, Income Taxes The Company maintains a valuation allowance with respect to deferred tax assets. The Company establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carry-forward period under the federal tax laws. Changes in circumstances, including the Company generating significant taxable income, could cause a change in judgment about the reliability of the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate. Estimates The financial statements are prepared on the basis of accounting principles generally accepted in the United States of America, also referred to as U.S. GAAP. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the dates of the balance sheets and the income and expenses for the periods ended as stated in the statements of operations. Revenue Recognition The Company recognizes consulting income in accordance with ASC 606. This standard’s stated core principle is that an entity should recognize revenue to depict the transfer of promised services or goods to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 includes provisions within a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. Our consulting revenues currently consist of consulting contracts for professional services that are performed over a stated period of time. We recognize income for each contract on a pro-rata basis over the stated period of time as we satisfy a performance obligation. The Company recognizes loan origination fees in accordance with ASC Topic 310-20, “Receivables Nonrefundable Fees and Other Costs” and records these fees as “Other Income.” Accordingly, revenue from loan origination fees, net of their direct costs, are deferred and amortized over the life of the loan to which they relate. Loan origination fees include fees for services and costs to originate, renew or restructure a loan, including costs directly related to evaluating the financial performance of the potential borrower and preparing loan documentation. Currently, the Company considers the costs of the loan origination fees to be immaterial for financial reporting purposes and therefore does not directly allocate the costs of these services. Our origination fees currently consist of our debtor’s stock that we have received from originating and renewing certain loans to the debtor. The amount of the origination fee is determined as the value of the stock on the sooner of the first date the Company receives the debtor’s stock without a restricted stock legend, or the first date the Company can otherwise ascertain the readily determinable value of the debtor’s stock. In accordance with “ASC 321 Investments – Equity Securities,” described below, if stock or other equity securities are received for consulting income or origination fees then the value is measured at the cost of the equity securities minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined, for the identical or a similar investment of the same issuer. The Company considers equity securities that have a restricted stock legend that restricts their free trading to have no readily determinable fair value, unless the Company can substantiate that a different value could be received for the identical or similar investment of the same issuer. Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment topic of Accounting Standards Codification (“ASC”) 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The Accounting Standards Codification also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the period of services or the vesting period, whichever is applicable. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expenses based on the fair value of the award at the reporting date. The awards to consultants and other third parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date. Subsequent Events The Company evaluated subsequent events through the date when these financial statements are issued for disclosure consideration. Adoption of Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that management of the Company believes may impact its financial statements, including ASC 842 described above under Right-of-Use Assets Lease Contracts Receivable Recent Accounting Pronouncements Effective December 1, 2017, the Company adopted Accounting Standards Update (“ASU”) 2016-01 “Financial Instruments—Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 adds a new Topic, “ASC 321 Investments – Equity Securities” to the FASB Accounting Standards Codification, which provides guidance on accounting for all equity investments. The guidance in ASC 321 allows a measurement exception for those equity investments that do not have a “readily determinable fair value,” as defined therein, and do not qualify to be measured using the practical expedient to estimate fair value at net asset value (NAV) of the investee in accordance with ASC 820-1035-59, Fair Value Measurement and Disclosure. The measurement alternative allows those investments to be measured at their cost minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined, for the identical or a similar investment of the same issuer. Hestia has elected to use this measurement exception. See Note 3 below for a detailed listing of the Company’s investment in equities to which the measurement exception applies.

Investment in Equities.

Investment in Equities.	6 Months Ended
	May 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
Investment in Equities.	Note 3 – Investment in Equities. The following equity investments that have a readily determinable fair value are measured using ASC Topic 820, discussed above. The following equities without a readily determinable fair value use the measurement alternative of ASC Topic 321 and are measured at their cost minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined, for the identical or a similar investment of the same issuer. Schedule of investment in equities Description How Acquired Readily Cost Current Changes Cumulative Impairments Prior Cumulative Adjust. May 31, Bal. Sheet Value 38,441,500 shares of restricted stock in Patient Access Solutions, Inc. (“PASO” on OTCMarkets.com) Origination Fees No $ 0 $ 0 $ 0 $ 0 $ 0 4,135,614 shares of restricted stock in Patient Access Solutions, Inc. (“PASO” on OTCMarkets.com) Consulting Income No $ 0 $ 0 $ 0 $ 0 $ 0 222 shares of unrestricted stock in Canibiola, Inc. (“CANB” on OTCMarkets.com) Consulting Income Yes $ 0 $ (18 ) $ 0 $ 140 $ 122 11,960,006 shares of unrestricted common stock in BHPA, Inc (“BHPA” on OTCMarkets.com) Consulting Income Yes $ 0 $ (29,900 ) $ 0 $ 149,500 $ 119,600 6,000 shares of Gabelli Equity Trust Inc. stock Purchase Yes $ 35,572 (2,215 ) 0 (1,137 ) $ 32,220 2,500 shares of Etao Intl. Co. Ltd. Common stock Purchase Yes $ 3,767 (2,617 ) 0 - $ 1,150 Totals $ 39,339 $ (34,750 ) $ 0 $ 148,503 $ 153,092

Income Taxes

Income Taxes	6 Months Ended
	May 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 4 – Income Taxes The Tax Cuts and Jobs Act (the “2017 Tax Act”) was enacted on December 22, 2017. The 2017 Tax Act includes a number of changes to existing U.S. income tax laws that affect the Company, most notably a reduction of the top U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The 2017 Tax Act also provides for the acceleration of depreciation for certain assets placed in service after September 27, 2017, as well as changes beginning in 2018, including additional limitations on the deductibility of executive compensation and interest. On May 16, 2019, the Company entered into a share exchange agreement which resulted in Hestia Investments, Inc. becoming a wholly owned subsidiary of the Company and the former shareholders Hestia Investments Inc becoming the new majority shareholders of the Company. Prior to this date the Company and Hestia Investments, Inc., have been taxed as separate C-Corporations for federal income tax purposes. The provision (benefit) for income taxes for six months ended May 31, 2023, and the year ended November 30, 2022, consist of the following: Schedule of provision for income taxes May 31, Nov. 30, Current: Federal $ 0 $ 0 State 0 0 Total Current $ 0 $ 0 Deferred: Federal $ 0 $ 0 State 0 0 Change in valuation 0 0 Total provision (benefit) $ 0 $ 0 The Company, and its subsidiary have net deferred tax assets resulting from net operating loss (“NOL”) carryforwards. These NOL carryforwards are subject to limitations on their use and availability. Under the 2017 Tax Act, NOL carryforwards can offset only 80% of taxable income in any given tax year and are significantly or completely reduced whenever there is a substantial change in the ownership of the Corporation. The income tax provision (benefit) differs from the amount computed by applying the U.S. federal statutory tax rate of 21% Schedule of reconciliation between provision for income taxes and income taxes at statutory U.S. federal income tax rate May 31, May 31, Net income (loss) before taxes $ (287,116 ) $ (1,679,091 ) US federal income tax rate 21 % 21 % Computed expected tax provision (benefit) (60,294 ) (352,609 ) Permanent differences - - Timing differences 60,294 352,609 Limitations on NOL carryforwards due to change in stock ownership of the Corporation Federal income tax provision $ - $ - The Company and its subsidiary file income tax returns in the U.S. federal jurisdiction and, if necessary, in various state and local jurisdictions. All tax years from 2017 to 2022 are subject to examination.

Related Party Transactions

Related Party Transactions	6 Months Ended
	May 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 – Related Party Transactions During the six months ended May 31, 2023, and the year ended November 30, 2022, the Company had no

Line of Credit Receivable from

Line of Credit Receivable from Patient Access Solutions, Inc.	6 Months Ended
	May 31, 2023
Receivables [Abstract]
Line of Credit Receivable from Patient Access Solutions, Inc.	Note 6 – Line of Credit Receivable from Patient Access Solutions, Inc. As of December 1, 2022, the total outstanding balance of $ 5,185 6%

Common Stock

Common Stock	6 Months Ended
	May 31, 2023
Equity [Abstract]
Common Stock	Note 7 – Common Stock On January 10, 2021, the Company issued 6,000 12,360 12,360 On March 1, 2021, Hestia Investments returned to the Company for cancellation its remaining 500,000 500,000 On January 20, 2022, the Company issued 15,000 48,750 48,750 On February 15, 2022, pursuant to an offering under Regulation A, the Company issued 8,060 26,195

Preferred Stock

Preferred Stock	6 Months Ended
	May 31, 2023
Equity [Abstract]
Preferred Stock	Note 8 – Preferred Stock The Company is authorized to issue up to 10,000,000 .00001 no

Options to Acquire Common Stock

Options to Acquire Common Stock	6 Months Ended
	May 31, 2023
Options To Acquire Common Stock
Options to Acquire Common Stock	Note 9 – Options to Acquire Common Stock On January 1, 2022, the Company issued Eugene Cha, Director, a stock option to acquire an aggregate of 60,000 5 3.50 1 60,000 no 1,200 0 On July 20, 2022, the Company issued Edward Boyle, Advisory Board member, a stock option to acquire an aggregate of 10,000 5 3.00 9 2,500 50 150 On December 15, 2022, the Company issued Dr. T.Z. (Ted) Chaung, Advisory Board member, a stock option to acquire an aggregate of 10,000 5 0.50 1 as of May 31, 2023, 4,583 options have vested and additional amounts of 2,500 shares vesting on each of the following dates: August 31, 2023; November 30, 2023, with the final 417 shares vesting on February 29, 2024. For the six-month period ending May 31, 2023, and the twelve-month period ending November 30, 2022, no options have been exercised and based on the Black-Scholes option-pricing model described below, no expense has been recorded for the Company. The estimated amount of expense for vested options is $975 and the amount for unvested options is $2,925. Black-Scholes option-pricing model. The Company recognizes the expense related to stock options it has provided individuals to acquire its common stock over the requisite service period (usually the vesting period of one year), utilizing the Black-Scholes option-pricing model. The volatility component of the calculation is based on the historic volatility of the Company’s stock, or the expected future volatility and it is assumed to be 77% 0.545

Subsequent Events

Subsequent Events	6 Months Ended
	May 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events The Company evaluates events that occur after the period’s end date through the date the financial statements are available to be issued. Accordingly, management has evaluated subsequent events through the date these financial statements are issued and has determined that no subsequent events require disclosure in these financial statements.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	May 31, 2023
Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of reporting within the balance sheets and the statements of cash flows, the Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, cash on deposit in attorney trust accounts, and all highly liquid debt instruments purchased with a maturity of six months or less to be cash and cash equivalents.
Prepaid Expenses	Prepaid Expenses The Company records amounts which have been paid in advance of receiving future economic benefits anticipated by the payment as prepaid expenses. Prepaid expenses are recorded as assets and expensed over the period that the benefits are received from the payment. The Company recorded as prepaid expenses of $ 0 0
Right-of-Use Assets	Right-of-Use Assets The Company recognizes operating lease assets and lease liabilities in accordance with ASU 2016-02, “Leases (Topic 842).” ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases and makes certain changes to the accounting for lease expenses. The Company has adopted this standard starting for the year ending November 30, 2020, the first year the Company had any leased assets. This standard requires us to increase our assets and liabilities by equal amounts through the recognition of right-of-use assets and lease liabilities for our operating leases and to recognize the initial and the monthly payments as operating expenses when paid or accrued on our Consolidated Statements of Operations and Consolidated Statements of Cash Flows. On November 2, 2020, the Company entered into an operating lease to lease an automobile for a net initial payment of $ 4,029 627 3,763 3,763 3,136 3,136
Lease Contracts Receivable	Lease Contracts Receivable The Company recognizes its participation as a lessor in direct financing leases in accordance with ASU 2016-02, “Leases (Topic 842).” Topic 842 is now recognized as ASC 842 and the Company has adopted this new standard effective for all fiscal years starting on and after December 1, 2021. In accordance with ASC 842 the Company does not recognize the ownership of assets as a lessor in direct financing lease arrangements. Instead, when the Company originates the lease, it records a net investment in the lease on the balance sheet. The asset amount is a lease contract receivable equal to the present value of all the lease payments to be received and listed as both short term and long-term receivables on the balance sheet. The liability amount is equal to the difference between the present value of the lease contract receivable and the cost of leased equipment. The liability amount represents the unearned interest income that will be earned by the lessor over the term of the lease, and it is listed as u On December 2, 2021, the Company entered into a direct financing lease as a lessor of $ 68,255 2,500 90,000 68,255 21,745 0 3,020
Termination of Lease Contracts Receivable	Termination of Lease Contracts Receivable In accordance with ASC 842 and ASC 842-30-40 if a direct financing lease is terminated before the end of the lease term the Company will reclassify the net investment in the lease as a fixed asset. The value of the fixed asset is equal to the net lease asset amount (the lease asset amount less the lease liability amount) at the time of termination reduced by any impairment in the value in the fixed asset. On December 1, 2022, the Company terminated the above-described direct financing lease due to lack of payment from the lessee and repossessed the computer equipment. At the time of the termination, the net investment in the lease was recorded as a $54,983 fixed asset of computer equipment calculated as the net of a $72,500 asset as a lease contract receivable less a $17,517 liability as unearned income on the lease receivable. On April 4, 2023, the Company sold the equipment for $ 27,000 25,233
Investments in Equities	Investments in Equities ASC Topic 820, Fair Value Measurements and Disclosures ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows: ● Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. For those investments in equities, including equity securities and partnership interests, that have a “readily determinable fair value,” as defined in ASC Topic 321 and discussed below, or are traded in a verifiable public market and are not restricted for sale in the public market by a restricted stock legend, or can otherwise be reasonably valued using the three levels of the fair value hierarchy under ASC Topic 820 discussed above, we present and carry our investments at their estimate of fair value at net asset value (NAV) as of the balance sheet date. For these equity securities and partnership interests we include the realized and unrealized gains and losses arising from the changes in the fair values during the period as a component of investment gains in the consolidated statements of operations. For those investments in equities, including equity securities and partnership interests, that do not have a “readily determinable fair value,” or are not traded in a verifiable public market or are restricted for sale in the public market by a restricted stock legend or otherwise, we present and carry our investments using the measurement alternative which is cost minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined in ASC 321, for the identical or a similar investment of the same issuer.
Income Taxes	Income Taxes The Company accounts for income taxes pursuant to FASB ASC Topic 740, Income Taxes The Company maintains a valuation allowance with respect to deferred tax assets. The Company establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carry-forward period under the federal tax laws. Changes in circumstances, including the Company generating significant taxable income, could cause a change in judgment about the reliability of the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.
Estimates	Estimates The financial statements are prepared on the basis of accounting principles generally accepted in the United States of America, also referred to as U.S. GAAP. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the dates of the balance sheets and the income and expenses for the periods ended as stated in the statements of operations.
Revenue Recognition	Revenue Recognition The Company recognizes consulting income in accordance with ASC 606. This standard’s stated core principle is that an entity should recognize revenue to depict the transfer of promised services or goods to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 includes provisions within a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. Our consulting revenues currently consist of consulting contracts for professional services that are performed over a stated period of time. We recognize income for each contract on a pro-rata basis over the stated period of time as we satisfy a performance obligation. The Company recognizes loan origination fees in accordance with ASC Topic 310-20, “Receivables Nonrefundable Fees and Other Costs” and records these fees as “Other Income.” Accordingly, revenue from loan origination fees, net of their direct costs, are deferred and amortized over the life of the loan to which they relate. Loan origination fees include fees for services and costs to originate, renew or restructure a loan, including costs directly related to evaluating the financial performance of the potential borrower and preparing loan documentation. Currently, the Company considers the costs of the loan origination fees to be immaterial for financial reporting purposes and therefore does not directly allocate the costs of these services. Our origination fees currently consist of our debtor’s stock that we have received from originating and renewing certain loans to the debtor. The amount of the origination fee is determined as the value of the stock on the sooner of the first date the Company receives the debtor’s stock without a restricted stock legend, or the first date the Company can otherwise ascertain the readily determinable value of the debtor’s stock. In accordance with “ASC 321 Investments – Equity Securities,” described below, if stock or other equity securities are received for consulting income or origination fees then the value is measured at the cost of the equity securities minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined, for the identical or a similar investment of the same issuer. The Company considers equity securities that have a restricted stock legend that restricts their free trading to have no readily determinable fair value, unless the Company can substantiate that a different value could be received for the identical or similar investment of the same issuer.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment topic of Accounting Standards Codification (“ASC”) 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The Accounting Standards Codification also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the period of services or the vesting period, whichever is applicable. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expenses based on the fair value of the award at the reporting date. The awards to consultants and other third parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.
Subsequent Events	Subsequent Events The Company evaluated subsequent events through the date when these financial statements are issued for disclosure consideration.
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that management of the Company believes may impact its financial statements, including ASC 842 described above under Right-of-Use Assets Lease Contracts Receivable
Recent Accounting Pronouncements	Recent Accounting Pronouncements Effective December 1, 2017, the Company adopted Accounting Standards Update (“ASU”) 2016-01 “Financial Instruments—Recognition and Measurement of Financial Assets and Financial Liabilities.” ASU 2016-01 adds a new Topic, “ASC 321 Investments – Equity Securities” to the FASB Accounting Standards Codification, which provides guidance on accounting for all equity investments. The guidance in ASC 321 allows a measurement exception for those equity investments that do not have a “readily determinable fair value,” as defined therein, and do not qualify to be measured using the practical expedient to estimate fair value at net asset value (NAV) of the investee in accordance with ASC 820-1035-59, Fair Value Measurement and Disclosure. The measurement alternative allows those investments to be measured at their cost minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined, for the identical or a similar investment of the same issuer. Hestia has elected to use this measurement exception. See Note 3 below for a detailed listing of the Company’s investment in equities to which the measurement exception applies.

Investment in Equities. (Tables

Investment in Equities. (Tables)	6 Months Ended
	May 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
Schedule of investment in equities	Schedule of investment in equities Description How Acquired Readily Cost Current Changes Cumulative Impairments Prior Cumulative Adjust. May 31, Bal. Sheet Value 38,441,500 shares of restricted stock in Patient Access Solutions, Inc. (“PASO” on OTCMarkets.com) Origination Fees No $ 0 $ 0 $ 0 $ 0 $ 0 4,135,614 shares of restricted stock in Patient Access Solutions, Inc. (“PASO” on OTCMarkets.com) Consulting Income No $ 0 $ 0 $ 0 $ 0 $ 0 222 shares of unrestricted stock in Canibiola, Inc. (“CANB” on OTCMarkets.com) Consulting Income Yes $ 0 $ (18 ) $ 0 $ 140 $ 122 11,960,006 shares of unrestricted common stock in BHPA, Inc (“BHPA” on OTCMarkets.com) Consulting Income Yes $ 0 $ (29,900 ) $ 0 $ 149,500 $ 119,600 6,000 shares of Gabelli Equity Trust Inc. stock Purchase Yes $ 35,572 (2,215 ) 0 (1,137 ) $ 32,220 2,500 shares of Etao Intl. Co. Ltd. Common stock Purchase Yes $ 3,767 (2,617 ) 0 - $ 1,150 Totals $ 39,339 $ (34,750 ) $ 0 $ 148,503 $ 153,092

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	May 31, 2023
Income Tax Disclosure [Abstract]
Schedule of provision for income taxes	Schedule of provision for income taxes May 31, Nov. 30, Current: Federal $ 0 $ 0 State 0 0 Total Current $ 0 $ 0 Deferred: Federal $ 0 $ 0 State 0 0 Change in valuation 0 0 Total provision (benefit) $ 0 $ 0
Schedule of reconciliation between provision for income taxes and income taxes at statutory U.S. federal income tax rate	Schedule of reconciliation between provision for income taxes and income taxes at statutory U.S. federal income tax rate May 31, May 31, Net income (loss) before taxes $ (287,116 ) $ (1,679,091 ) US federal income tax rate 21 % 21 % Computed expected tax provision (benefit) (60,294 ) (352,609 ) Permanent differences - - Timing differences 60,294 352,609 Limitations on NOL carryforwards due to change in stock ownership of the Corporation Federal income tax provision $ - $ -

Summary of significant accoun_3

Summary of significant accounting policies (Details Narrative) - USD ($)					6 Months Ended
	Apr. 04, 2023	Dec. 02, 2021	Dec. 02, 2020	Nov. 02, 2020	May 31, 2023	May 31, 2022	Nov. 30, 2022
Prepaid expenses					$ 0		$ 0
Operating lease liability non current					3,763	$ 3,763
Right of use assets					3,136		$ 6,900
Right of use liability					3,136
Contract lease receivable		$ 90,000
Asset net		68,255
Unearned income on lease receivable		$ 21,745
Interest income on lease receivable					$ 0	$ 3,020
Financing lease decription					the net investment in the lease was recorded as a $54,983 fixed asset of computer equipment calculated as the net of a $72,500 asset as a lease contract receivable less a $17,517 liability as unearned income on the lease receivable.
Proceeds used in purchase of investment equities	$ 27,000
Realized loss on sale of capital assets	$ 25,233				$ 25,233
Automobile [Member]
Operating lease payment				$ 4,029	$ 627
Finance lease payment			$ 68,255
Monthly payments			$ 2,500

Investment in Equities (Details

Investment in Equities (Details)	6 Months Ended
	May 31, 2023 USD ($)
Schedule of Investments [Line Items]
Investment in Equities, Cost	$ 39,339
Investment in Equities, Current Changes	(34,750)
Investment in Equities, Cumulative Impairments	0
Investment in Equities, Prior Cumulative Adjustment	148,503
Investment in Equities, Value	$ 153,092
Investment [Member]
Schedule of Investments [Line Items]
Investment in Equities, Description	38,441,500 shares of restricted stock in Patient Access Solutions, Inc. (“PASO” on OTCMarkets.com)
Investment in Equities, How Acquired	Origination Fees
Investment in Equities, Readily Determinable Fair Value	No
Investment in Equities, Cost	$ 0
Investment in Equities, Current Changes	0
Investment in Equities, Cumulative Impairments	0
Investment in Equities, Prior Cumulative Adjustment	0
Investment in Equities, Value	$ 0
Investment 1 [Member]
Schedule of Investments [Line Items]
Investment in Equities, Description	4,135,614 shares of restricted stock in Patient Access Solutions, Inc. (“PASO” on OTCMarkets.com)
Investment in Equities, How Acquired	Consulting Income
Investment in Equities, Readily Determinable Fair Value	No
Investment in Equities, Cost	$ 0
Investment in Equities, Current Changes	0
Investment in Equities, Cumulative Impairments	0
Investment in Equities, Prior Cumulative Adjustment	0
Investment in Equities, Value	$ 0
Investment 2 [Member]
Schedule of Investments [Line Items]
Investment in Equities, Description	222 shares of unrestricted stock in Canibiola, Inc. (“CANB” on OTCMarkets.com)
Investment in Equities, How Acquired	Consulting Income
Investment in Equities, Readily Determinable Fair Value	Yes
Investment in Equities, Cost	$ 0
Investment in Equities, Current Changes	(18)
Investment in Equities, Cumulative Impairments	0
Investment in Equities, Prior Cumulative Adjustment	140
Investment in Equities, Value	$ 122
Investment 3 [Member]
Schedule of Investments [Line Items]
Investment in Equities, Description	11,960,006 shares of unrestricted common stock in BHPA, Inc (“BHPA” on OTCMarkets.com)
Investment in Equities, How Acquired	Consulting Income
Investment in Equities, Readily Determinable Fair Value	Yes
Investment in Equities, Cost	$ 0
Investment in Equities, Current Changes	(29,900)
Investment in Equities, Cumulative Impairments	0
Investment in Equities, Prior Cumulative Adjustment	149,500
Investment in Equities, Value	$ 119,600
Investment 4 [Member]
Schedule of Investments [Line Items]
Investment in Equities, Description	6,000 shares of Gabelli Equity Trust Inc. stock
Investment in Equities, How Acquired	Purchase
Investment in Equities, Readily Determinable Fair Value	Yes
Investment in Equities, Cost	$ 35,572
Investment in Equities, Current Changes	(2,215)
Investment in Equities, Cumulative Impairments	0
Investment in Equities, Prior Cumulative Adjustment	(1,137)
Investment in Equities, Value	$ 32,220
Investment 5 [Member]
Schedule of Investments [Line Items]
Investment in Equities, Description	2,500 shares of Etao Intl. Co. Ltd. Common stock
Investment in Equities, How Acquired	Purchase
Investment in Equities, Readily Determinable Fair Value	Yes
Investment in Equities, Cost	$ 3,767
Investment in Equities, Current Changes	(2,617)
Investment in Equities, Cumulative Impairments	0
Investment in Equities, Prior Cumulative Adjustment
Investment in Equities, Value	$ 1,150

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2023	May 31, 2022	May 31, 2023	May 31, 2022
Current:
Federal			$ 0	$ 0
State			0	0
Total Current			0	0
Deferred:
Federal			0	0
State			0	0
Change in valuation			0	0
Total provision (benefit)	$ 0	$ 0	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2023	May 31, 2022	May 31, 2023	May 31, 2022
Income Tax Disclosure [Abstract]
Net income (loss) before taxes			$ (287,116)	$ (1,679,091)
US federal income tax rate			21%	21%
Computed expected tax provision (benefit)			$ (60,294)	$ (352,609)
Permanent differences
Timing differences			60,294	352,609
Federal income tax provision	$ 0	$ 0	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	6 Months Ended
	May 31, 2023	May 31, 2022
Income Tax Disclosure [Abstract]
US federal income tax rate	21%	21%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	6 Months Ended
	May 31, 2023	May 31, 2022
ECL Capital Partners Corp. [Member]
Related Party Transaction [Line Items]
Revenues from related party	$ 0	$ 0

Line of Credit Receivable fro_2

Line of Credit Receivable from Patient Access Solutions, Inc. (Details Narrative)	Dec. 02, 2022 USD ($)
Receivables [Abstract]
Outstanding balance	$ 5,185
Interest unsecured	6%

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)			1 Months Ended
	Mar. 02, 2021	Jan. 10, 2021	Feb. 15, 2022	Jan. 20, 2022
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Shares retired and cancelled	500,000
Unrelated Independent Contractor [Member]
Class of Stock [Line Items]
Shares issued for services, shares		6,000		15,000
Shares issued for services, value		$ 12,360		$ 48,750
Shareholders [Member]
Class of Stock [Line Items]
Stock issued for cash, shares			8,060
Stock issued for cash, value			$ 26,195

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - $ / shares	May 31, 2023	Nov. 30, 2022
Equity [Abstract]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Options to Acquire Common Sto_2

Options to Acquire Common Stock (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended
	Dec. 15, 2022	Jul. 20, 2022	May 31, 2023	Nov. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Vested options		$ 50		$ 1,200
Vested and additional description			as of May 31, 2023, 4,583 options have vested and additional amounts of 2,500 shares vesting on each of the following dates: August 31, 2023; November 30, 2023, with the final 417 shares vesting on February 29, 2024. For the six-month period ending May 31, 2023, and the twelve-month period ending November 30, 2022, no options have been exercised and based on the Black-Scholes option-pricing model described below, no expense has been recorded for the Company. The estimated amount of expense for vested options is $975 and the amount for unvested options is $2,925.
Volatility			77%
Stock price			$ 0.545
Eugene Cha [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock option granted	10,000	10,000	60,000
Exercise term	5 years	5 years	5 years
Exercise price	$ 0.50	$ 3	$ 3.50
Vesting term	1 year	9 years	1 year
Number of shares vested		2,500	60,000
Option exercised			0
Option expenses		$ 150	$ 0